Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2013 Nov 18;13(1):60–70. doi: 10.1158/1535-7163.MCT-13-0518

Figure 5.

Figure 5

The p110α-specific PI3K inhibitor BYL719 overcomes lapatinib resistance in vitro. (a) LapR cells were treated as shown for 4 days followed by MTT assay. Error bars, s.e.m. BYL and Lap. indicate BYL719 and lapatinib, respectively. (b) LapR cells were treated as shown for 3 hours followed by western blot. (c) LapR cells were treated as shown for 3 days followed by propidium iodide staining and flow cytometric cell cycle analysis. (d) Quantification of cell cycle analysis in (c). Comb indicates lapatinib plus BYL719 combination. Sub-G1 and super-G2 cells were excluded. (p < 0.0001 in panel (a) is by one-way ANOVA of lapatinib-treated groups with post-test for linear trend to analyze dose-dependent effect.)